臨床血液
Online ISSN : 1882-0824
Print ISSN : 0485-1439
ISSN-L : 0485-1439
臨床研究
小児急性前骨髄球性白血病(FAB M3)の晩期再発
—小児急性非リンパ性白血病の治療成績からみたM3例の特殊性—
東道 伸二郎, 新川 正治, 長井 隆夫, 綱本 健太郎, 橋田 哲夫, 江角 典子, 清水 芳隆, 藤原 史博, 日比 成美, 吉原 隆夫, 生島 聡, 今宿 晋作, 森岡 義仁, 泉 均, 大塚 拓治, 藤田 克寿
著者情報
ジャーナル 認証あり

1988 年 29 巻 2 号 p. 137-143

詳細
抄録
During the past 6 years from 1981 through 1986, a total of 33 new cases of childhood acute non-lymphoblastic leukemia (ANLL) were treated with an intensive multi-drug chemotherapy at the Department of Pediatrics, Kyoto Prefectural University of Medicine and other affiliated pediatric clinics.
Excluding 2 cases still receiving early induction therapy, 24 of the remaining 31 cases (78%) attained complete remission (CR); a half of which relapsed or died within 15 months, but another half had, or has been in continuous complete remission (CCR) for over 24 months after beginning of the induction therapy.
All of the 5 M3 patients attained CR and had or has been in CCR over 24 months, indicating that M3 cases easily achieve long term CR. On the other hand, 19 of the other 26 ANLL cases attained CR but only 7 cases had or has been in CCR over 24 months. However, late relapse after 24 months occurred in 3 of the 5 M3 cases, compared with 1 in the 7 other ANLL cases.
Our results may suggest that protocols for M3 cases should be modified to include more intensified, and long-duration maintenance chemotherapy, in order to prevent late relapse.
著者関連情報
© 1988 日本臨床血液学会
前の記事 次の記事
feedback
Top